Biolase, Inc.
BIOL
BIOL was delisted on the 18th of June, 2024.
32 hedge funds and large institutions have $14.8M invested in Biolase, Inc. in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 12 closing their positions.
380% more capital invested
Capital invested by funds: $3.07M → $14.8M (+$11.7M)
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
33% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 12
10% more funds holding
Funds holding: 29 → 32 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.95M |
| 2 |
BlackRock
New York
|
+$3.26M |
| 3 |
Renaissance Technologies
New York
|
+$2.01M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$678K |
| 5 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$430K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$725K |
| 2 |
Squarepoint
New York
|
-$489K |
| 3 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$253K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$82K |
| 5 |
WPC
White Pine Capital
Bloomington,
Minnesota
|
-$73K |
BIOL Hedge Fund Activity: Q1 2021 in Review
32 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q1 2021, worth a combined $14.8M — up 380% from $3.07M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new BIOL positions and 12 closed out — a net gain of 4 holders — while 8 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $5.95M. The largest seller was Oracle Investment Management, exiting entirely with an estimated $725K sold.
- 32 institutional investors held Biolase, Inc. (BIOL) as of Q1 2021, up from 29 in Q4 2020.
- Funds reported $14.8M of Biolase, Inc. stock for Q1 2021, up 380% quarter-over-quarter.
- 16 funds opened new Biolase, Inc. positions in Q1 2021 and 12 closed out, a net change of +4 holders.
- The largest Biolase, Inc. buyer in Q1 2021 was Vanguard Group, an estimated $5.95M added.
- The largest Biolase, Inc. seller in Q1 2021 was Oracle Investment Management, an estimated $725K sold.
Based on aggregated 13F filings for Q1 2021.